Phase II Study of Bryostatin-1 in Metastatic Renal Cell Carcinoma(Summary Last Modified 8/1999)
I. Determine the objective response rate to bryostatin 1 in patients with advanced renal
II. Assess the toxicities of this treatment regimen in this patient population. III.
Determine the time to disease progression in patients receiving this treatment regimen.
IV. Determine the overall survival of this patient population treated with this regimen.
Patients receive bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment continues every
4 weeks in the absence of unacceptable toxicity or disease progresssion.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Naomi S. Balzer-Haas, MD
Fox Chase Cancer Center
United States: Food and Drug Administration
|Fox Chase Cancer Center||Philadelphia, Pennsylvania 19111|
|South Jersey Hospital - Millville||Millville, New Jersey 08332|
|Fox Chase Cancer Center at Virtua-Memorial Hospital Burlington County||Mount Holly, New Jersey 08060|
|Community Medical Center||Toms River, New Jersey 08755|
|St. Francis Medical Center||Trenton, New Jersey 08629|
|Delaware County Memorial Hospital||Drexel Hill, Pennsylvania 19026|
|Reading Hospital and Medical Center||Reading, Pennsylvania 19612-6052|
|Hunterdon Regional Cancer Center||Flemington, New Jersey 08822|
|Riverview Medical Center||Red Bank, New Jersey 07701|
|Kimball Medical Center||Lakewood, New Jersey 08701|
|North Penn Hospital||Lansdale, Pennsylvania 19446-1200|
|Paoli Memorial Hospital||Paoli, Pennsylvania 19301-1792|
|Pinnacle Health Hospitals||Harrisburg, Pennsylvania 17105-8700|
|Conemaugh Memorial Hospital||Johnstown, Pennsylvania 15905|
|Pottstown Memorial Regional Cancer Center||Pottstown, Pennsylvania 19464|
|Bon Secours-Holy Family Health System||Altoona, Pennsylvania 16602|
|Saint Mary Medical Center||Langhorne, Pennsylvania 19047|